Information Provided By:
Fly News Breaks for March 22, 2019
IONS, IONS
Mar 22, 2019 | 04:55 EDT
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Ionis Pharmaceuticals following the "positive" Phase 3 protocol amendment for its Roche-partnered Huntington's program for IONIS-HTT-Rx and introduction of more convenient monthly dosing. Less frequent dosing should support more rapid enrollment in the Phase 3 study, Birchenough tells investors in a research note. He believes the timelines for a potential accelerated approval filing on Phase 1 data is intact with an expected FDA meeting by the end of 2019. The analyst sees "significant upside potential" for Ionis shares and maintains a $106 price target.
News For IONS From the Last 2 Days
IONS
Mar 28, 2024 | 10:40 EDT
Meetings to be held in Los Angeles on April 2 and in San Francisco on April 3 hosted by Piper Sandler.